AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31110092 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 126
Study 27707990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (1.5 g IV every 8 h)
Number of subjects: 1346
Study 27707990 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (750 mg once daily)
Number of subjects: 1346
Study 27707990 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g IV every 8 h)
Number of subjects: 1346
Study 26666319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg per day)
Number of subjects: 35
Study 26666319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 100
Study 24157825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in women without insulin resistance)
Number of subjects: 100
Study 24157825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in women without insulin resistance)
Number of subjects: 100
Study 24157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in women with insulin resistance)
Number of subjects: 100
Study 24157825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in women with insulin resistance)
Number of subjects: 100
Study 20808151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy (information leaflet and self-help manual 'Coping with Depression')
Number of subjects: 170
Study 20808151 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 170
Study 19537838 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 19537838 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 or 120 mg/day
Number of subjects: 0
Study 19537838 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 16953132 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification program (16 weeks, weekly meetings, individually prescribed exercise and diet, stress management, self-monitoring)
Number of subjects: 34
Study 16953132 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 34
Study 12773196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg ghrelin
Number of subjects: 6
Study 12773196 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg ghrelin
Number of subjects: 6
Study 12773196 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg ghrelin
Number of subjects: 6
Study 10839470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg 12‐hourly for 48 hours
Number of subjects: 35
Study 10839470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 35
Study 10322847 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangtangkang (JTK), 8 g each time, 3 times per day for 2 months
Number of subjects: 188
Study 10322847 — intervention group
Group type: COMPARATOR
Intervention: Control group (Glibenclazide for newly discovered NIDDM, no treatment for poorly controlled NIDDM)
Number of subjects: 188
Study 8489450 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006%) twice daily during week 1 and pilocarpine (2%) three times daily during week 2
Number of subjects: 20
Study 8489450 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (2%) three times daily during week 1 and PhXA41 (0.006%) twice daily during week 2
Number of subjects: 20
Study 3501692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and antacid
Number of subjects: 106
Study 3501692 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 106
Study 31718504 — intervention group
Group type: EXPERIMENTAL
Intervention: Journal interventions (e.g., Basic Science Checklist by Stroke)
Number of subjects: 4162
Study 31718504 — intervention group
Group type: COMPARATOR
Intervention: Control journals (without analogous interventions)
Number of subjects: 4162
Study 29394998 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin + a glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602
Study 29394998 — intervention group
Group type: COMPARATOR
Intervention: bivalirudin
Number of subjects: 3602
Study 27117698 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (5 mg/kg) administered intravenously every 8 weeks from week 62 to week 102
Number of subjects: 174
Study 25586332 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with microskin autografting
Number of subjects: 81
Study 25586332 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze with microskin autografting
Number of subjects: 81
Study 24257391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (PNB) with 0.3 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Number of subjects: 80
Study 24257391 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (CB) with 1 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Number of subjects: 80
Study 20876551 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counseling intervention provided by a lactation consultant-peer counselor team
Number of subjects: 289
Study 20876551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 289
Study 18571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulating diet (IMEN group)
Number of subjects: 183
Study 18571296 — intervention group
Group type: COMPARATOR
Intervention: Standard oligopeptic diet (SEN group)
Number of subjects: 183
Study 17138304 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music with vocals
Number of subjects: 2
Study 17138304 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music without vocals
Number of subjects: 2
Study 17138304 — intervention group
Group type: COMPARATOR
Intervention: Both types of music
Number of subjects: 2
Study 12892243 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb interval training (3 sessions of 30 minutes per week for 6 weeks)
Number of subjects: 14
Study 12892243 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb interval training
Number of subjects: 14
Study 12892243 — intervention group
Group type: COMPARATOR
Intervention: Control group (general rehabilitation only)
Number of subjects: 14
Study 11054030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (imipramine plus oxybutynin)
Number of subjects: 77
Study 11054030 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 77
Study 9202790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density formula (30 kcal/oz) at 145 ml/kg/day
Number of subjects: 60
Study 9202790 — intervention group
Group type: COMPARATOR
Intervention: Low-density formula (24 kcal/oz) at 180 ml/kg/day
Number of subjects: 60
Study 9202790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density formula (30 kcal/oz)
Number of subjects: 60
Study 9202790 — intervention group
Group type: COMPARATOR
Intervention: Low-density formula (24 kcal/oz)
Number of subjects: 60
Study 7972390 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate bar
Number of subjects: 0
Study 7972390 — intervention group
Group type: EXPERIMENTAL
Intervention: White chocolate
Number of subjects: 0
Study 7972390 — intervention group
Group type: COMPARATOR
Intervention: Cocoa capsules (pharmacological equivalent)
Number of subjects: 0
Study 7972390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7972390 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 2537349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (10 capsules/day, 1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid)
Number of subjects: 108
Study 2537349 — intervention group
Group type: COMPARATOR
Intervention: Control (10 capsules of 50% olive oil, 50% corn oil)
Number of subjects: 108
Study 2537349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 108
Study 2537349 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study 4557030 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 63
Study 4557030 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone
Number of subjects: 63
Study 30609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app and wearable device users
Number of subjects: 60
Study 30609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-only users
Number of subjects: 60
Study 30609978 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 28285749 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially delivered 12-week lifestyle behavioral program
Number of subjects: 88
Study 28285749 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 88
Study 26271843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic contact lens (CL)
Number of subjects: 114
Study 26271843 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL)
Number of subjects: 114
Study 26271843 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (Control)
Number of subjects: 114
Study 26271843 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated eyes with glaucoma
Number of subjects: 114
Study 26271843 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated eyes with glaucoma suspect
Number of subjects: 114
Study 24189171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine with sorafenib 400mg bid (arm A)
Number of subjects: 114
Study 24189171 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine without sorafenib (arm B)
Number of subjects: 114
Study 22848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest (BR) for 8 days
Number of subjects: 9
Study 22848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest (BR) for 35 days
Number of subjects: 9
Study 22848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Bed Rest campaign
Number of subjects: 9
Study 22848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest (BR)
Number of subjects: 9
Study 19392995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for pollen allergens
Number of subjects: 0
Study 17316169 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 200mg/day
Number of subjects: 333
Study 17316169 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 100mg/day
Number of subjects: 333
Study 17316169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 15062892 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for 4 months
Number of subjects: 50
Study 15062892 — intervention group
Group type: COMPARATOR
Intervention: Health education control for 4 months
Number of subjects: 50
Study 11577374 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg, b.i.d.)
Number of subjects: 391
Study 11577374 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 391
Study 11577374 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 391
Study 9850026 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP (both standard and escalated dose)
Number of subjects: 505
Study 9850026 — intervention group
Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 505
Study 9850026 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 505
Study 9850026 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BEACOPP
Number of subjects: 505
Study 7720940 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months nafarelin followed by 3 months of placebo (n = 91)
Number of subjects: 179
Study 7720940 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months nafarelin (n = 88)
Number of subjects: 179
Study 2404528 — intervention group
Group type: EXPERIMENTAL
Intervention: BAVC regimen (BCNU, amsacrine, VP‐16 (etoposide) and Ara‐C)
Number of subjects: 39
Study 2404528 — intervention group
Group type: EXPERIMENTAL
Intervention: CY + TBI regimen (cyclophosphamide/total body irradiation)
Number of subjects: 39
Study 7401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as Jello
Number of subjects: 0
Study 7401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as frozen Tang
Number of subjects: 0
Study 7401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet prepared with Flavor Packets
Number of subjects: 0
Study 7401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as Kool-Aid
Number of subjects: 0
Study 7401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B
Number of subjects: 0
Study 31810064 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20
Study 31810064 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise Training (MICE)
Number of subjects: 20
Study 31175583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet pattern
Number of subjects: 0
Study 31175583 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study 31175583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary quality measured by Healthy Eating Index score
Number of subjects: 0
Study 28589965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment (2 sessions)
Number of subjects: 47
Study 28589965 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 47
Study 25883130 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Sibs program (intervention group)
Number of subjects: 0
Study 25883130 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 23764690 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual titration of paroxetine (2.5 mg on alternate days up to 10 mg in 7 days)
Number of subjects: 50
Study 23764690 — intervention group
Group type: COMPARATOR
Intervention: Abrupt initiation of paroxetine (10 mg)
Number of subjects: 50
Study 21425721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise every day (G1)
Number of subjects: 68
Study 21425721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise three days per week (G2)
Number of subjects: 68
Study 21425721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus abdominal training three days per week (G3)
Number of subjects: 68
Study 21425721 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 68
Study 19918629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression
Number of subjects: 28
Study 19918629 — intervention group
Group type: EXPERIMENTAL
Intervention: Air stacking
Number of subjects: 28
Study 19918629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique (air stacking and chest compression)
Number of subjects: 28
Study 19918629 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 28
Study 16821647 — intervention group
Group type: EXPERIMENTAL
Intervention: New didanosine formulation (100 mg tablets)
Number of subjects: 0
Study 16821647 — intervention group
Group type: COMPARATOR
Intervention: Conventional didanosine formulation (100 mg tablets)
Number of subjects: 0
Study 12778041 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet
Number of subjects: 30
Study 12778041 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT ketogenic diet
Number of subjects: 30
Study 11372387 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide combined with terbutaline
Number of subjects: 42
Study 11372387 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline with placebo (control group)
Number of subjects: 42
Study 2064401 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E solution (DL-alpha-tocopherol in dimethyl sulfoxide) applied to three nails for 6 months
Number of subjects: 1
Study 2064401 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl sulfoxide only applied to three nails for 6 months
Number of subjects: 1
Study 2064401 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E solution applied to all nails for an additional 6 months after initial treatment
Number of subjects: 1
Study 6133970 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 723
Study 6133970 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 723
Study 6133970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study 30172649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 193
Study 29996720 — intervention group
Group type: EXPERIMENTAL
Intervention: pl-VEGF165
Number of subjects: 48
Study 29996720 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 27265893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 2806
Study 23990336 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated call group (n=26)
Number of subjects: 50
Study 23990336 — intervention group
Group type: COMPARATOR
Intervention: Health information group (n=24)
Number of subjects: 50
Study 21927808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CP) using passive expiratory techniques
Number of subjects: 99
Study 21927808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CP)
Number of subjects: 99
Study 19906801 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (120 mg/d)
Number of subjects: 224
Study 19906801 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (80 mg/d)
Number of subjects: 224
Study 19906801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 17989574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) injections (0.3 mL on days 1, 3, and 5) plus 48 mg methylprednisolone
Number of subjects: 120
Study 17989574 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone (control group)
Number of subjects: 120
Study 17989574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) injections
Number of subjects: 120
Study 16009663 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident cerebrovascular events
Number of subjects: 5804
Study 16009663 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fatal myocardial infarction
Number of subjects: 5804
Study 16009663 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident vascular events
Number of subjects: 5804
Study 12444816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (50 mg/day)
Number of subjects: 334
Study 12444816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 12444816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 334
Study 12444816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg/day)
Number of subjects: 334
Study 10539823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise (40 minutes, 30 minutes at 60% of maximal oxygen consumption)
Number of subjects: 18
Study 8542863 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 2
Study 8542863 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 2
Study 2288653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 megaunits of rIFN a‐2b s.c. thrice weekly for 4 months
Number of subjects: 58
Study 2288653 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study 30215171 — intervention group
Group type: COMPARATOR
Intervention: Nutritional sodium selenate (0.32 mg, 3 times daily)
Number of subjects: 40
Study 30215171 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranutritional sodium selenate (10 mg, 3 times daily)
Number of subjects: 40
Study 30261375 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallis interspinous spacer implantation
Number of subjects: 77
Study 30261375 — intervention group
Group type: COMPARATOR
Intervention: Control group (lumbar discectomy without Wallis implantation)
Number of subjects: 77
Study 26455957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable soup with added monosodium L-glutamate (0.5 g/100 ml)
Number of subjects: 68
Study 26455957 — intervention group
Group type: COMPARATOR
Intervention: Control vegetable soup (without MSG)
Number of subjects: 68
Study 24470436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 6.5 mg/kg/day for 8 weeks
Number of subjects: 23
Study 24470436 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 23
Study 24043137 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib (doses increased from 4 to 30 mg, administered once daily)
Number of subjects: 54
Study 21105934 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills instruction/training in school
Number of subjects: 0
Study 21105934 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills training out of school
Number of subjects: 0
Study 21105934 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of life skills instruction in school
Number of subjects: 0
Study 18838929 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl = 140 mEq/L)
Number of subjects: 122
Study 18838929 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic fluids (NaCl <100 mEq/L)
Number of subjects: 122
Study 18838929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isotonic and hypotonic fluids
Number of subjects: 122
Study 16905851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl
Number of subjects: 30
Study 16905851 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 30
Study 12802717 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized phytodrug from Solanum chrysotrichum
Number of subjects: 101
Study 12802717 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 101
Study 11038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer support organizations
Number of subjects: 0
Study 11038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapies
Number of subjects: 0